Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) FCF Margin (2019 - 2025)

Avidity Biosciences (RNA) has disclosed FCF Margin for 7 consecutive years, with 4905.52% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 141453.0% year-over-year to 4905.52%, compared with a TTM value of 3071.48% through Dec 2025, down 24560.0%, and an annual FY2025 reading of 3476.81%, down 65093.0% over the prior year.
  • FCF Margin was 4905.52% for Q4 2025 at Avidity Biosciences, down from 1295.49% in the prior quarter.
  • Across five years, FCF Margin topped out at 905.88% in Q4 2023 and bottomed at 8174.32% in Q1 2025.
  • Average FCF Margin over 5 years is 2323.32%, with a median of 1691.28% recorded in 2022.
  • The sharpest move saw FCF Margin soared 235186bps in 2023, then plummeted -616204bps in 2025.
  • Year by year, FCF Margin stood at 1507.67% in 2021, then grew by 4bps to 1445.97% in 2022, then skyrocketed by 163bps to 905.88% in 2023, then plummeted by -485bps to 3490.99% in 2024, then plummeted by -41bps to 4905.52% in 2025.
  • Business Quant data shows FCF Margin for RNA at 4905.52% in Q4 2025, 1295.49% in Q3 2025, and 5154.17% in Q2 2025.